Print

Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Concludes Enrollment for the Phase III Study of StemEx┬«, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma  
2/13/2012 6:13:57 AM

JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma, who cannot find a family related, matched bone marrow donor.
//-->